Brookline downgraded CervoMed (CRVO) to Hold from Buy and suspended the firm’s price target on the shares following the failure of the company’s Phase 2b RewinD-LB trial of neflamapimod in dementia with Lewy bodies.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRVO: